C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 487/04 (2006.01) A61K 31/495 (2006.01) A61K 31/53 (2006.01) A61P 29/00 (2006.01) A61P 35/00 (2006.01) C07D 495/04 (2006.01)
Patent
CA 2670044
The present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, of Formula (I) that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors. The heterobicyclic metalloprolease inhibiting compounds of the present invention may be used in the treatment of metalloprotease mediated diseases, such as rheumatoid arthritis, osteoarthritis, abdominal aortic aneurysm, cancer, inflammation, atherosclerosis, multiple sclerosis, chronic obstructive pulmonary disease, ocular diseases, neurological diseases, psychiatric diseases, thrombosis, bacterial infection, Parkinson's disease, fatigue, tremor, diabetic retinopathy, vascular diseases of the retina, aging, dementia, cardiomyopathy, renal tubular impairment, diabetes, psychosis, dyskinesia, pigmentary abnormalities, deafness, inflammatory and fibrotic syndromes, intestinal bowel syndrome, allergies, Alzheimer's disease, arterial plaque formation, periodontal, viral infection, stroke, cardiovascular disease, reperfusion injury, trauma, chemical exposure or oxidative damage to tissues, wound healing, hemorroid, skin beautifying, pain, inflammatory pain, bone pain and joint pain.
La présente invention concerne généralement des agents pharmaceutiques hétérobicycliques contenant un amide, et en particulier, des composés inhibant des métalloprotéases hétérobicycliques contenant un amide. Plus particulièrement, la présente invention concerne une nouvelle classe de composés hétérobicycliques inhibant la MMP-3 et/ou la MMP-13, qui présentent un pouvoir et une sélectivité améliorés par rapport aux inhibiteurs de la MMP-13 et de la MMP-3 actuellement connus.
Bluhm Harald
Essers Michael
Gege Christian
Hochguertel Matthias
Kroth Heiko
Alantos Pharmaceuticals Holding Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Heterobicyclic matrix metalloprotease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterobicyclic matrix metalloprotease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterobicyclic matrix metalloprotease inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1521808